Skip to main content
. Author manuscript; available in PMC: 2012 Mar 24.
Published in final edited form as: N Engl J Med. 2011 Mar 24;364(12):1144–1153. doi: 10.1056/NEJMra1010600

Table 1.

Anticancer Drugs Approved by the Food and Drug Administration (FDA) with Labeling Regarding Pharmacogenomic Biomarkers.*

Type of Biomarker and Associated Drug
    Biomarker with pharmacokinetic effect
    TPMT
        Mercaptopurine
        Thioguanine
    UGT1A1
        Irinotecan
        Nilotinib
    Biomarker with pharmacodynamic effect
    EGFR
        Cetuximab
        Erlotinib
        Gefitinib
        Panitumumab
    KRAS
        Cetuximab
        Panitumumab
    ABL
        Imatinib
        Dasatinib
        Nilotinib
    C-Kit (KIT)
        Imatinib
    HER2/neu (ERBB2)
        Lapatinib
        Trastuzumab
    Estrogen receptor
        Tamoxifen
*

Data are from the FDA's pharmacogenetics Web site (www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm). The biomarkers have been separated into pharmacokinetic effect (drug metabolism) and pharmacodynamic effect (drug target). Biomarkers for cytogenetic alterations have been excluded.